{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:33:01Z","timestamp":1789237981716,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["4706174"],"award-info":[{"award-number":["4706174"]}],"id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010116","name":"Medicinska Underst\u00f6dsf\u00f6reningen Liv och H\u00e4lsa","doi-asserted-by":"publisher","award":["4708936"],"award-info":[{"award-number":["4708936"]}],"id":[{"id":"10.13039\/100010116","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010135","name":"Finska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","award":["4709232"],"award-info":[{"award-number":["4709232"]}],"id":[{"id":"10.13039\/100010135","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["4709194"],"award-info":[{"award-number":["4709194"]}],"id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","award":["TYH2020208"],"award-info":[{"award-number":["TYH2020208"]}],"id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004756","name":"Emil Aaltosen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","award":["210179"],"award-info":[{"award-number":["210179"]}],"id":[{"id":"10.13039\/501100004756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007797","name":"University of Helsinki","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Eccrine porocarcinoma (EPC) is a rare malignant skin tumor arising from the eccrine gland. Investigations into the genomic landscape of EPC have uncovered potential drivers of its development and progression. However, there is limited information on the discrepancies between EPC and its benign counterpart, eccrine poroma (EP).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Formalin-fixed paraffin-embedded (FFPE) samples from 15 EPCs and 5 EPs were retrieved from Helsinki Biobank and Finnish Clinical Biobank Tampere. One EPC was found to be digital papillary adenocarcinoma in review of diagnoses. Whole-exome sequencing was used to conduct a comprehensive analysis to elucidate the genomic features of EPCs and EPs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>There was general heterogeneity within EPCs and EPs, with discrepancies such as exclusive <jats:italic>TP53<\/jats:italic>, <jats:italic>NCOR1<\/jats:italic>, and <jats:italic>CDKN2A<\/jats:italic> mutations in EPCs and a higher mutational load in EPCs than in EPs. Furthermore, we identified alterations in pathways associated with cell adhesion and the extracellular matrix in EPCs, while pathways associated with ketone body and amino acid metabolism were altered in EPs. The MAPK and Ras signaling pathways were enriched in genes mutated only in EPCs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>EPCs and EPs are generally heterogeneous tumor entities with a few distinct discrepancies from each other. The findings from this study emphasize the need to further verify the roles of disrupted genes and pathways in the initiation and progression of EPCs and EPs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03586-7","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T08:27:44Z","timestamp":1739435264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Whole-exome sequencing identifies distinct genomic aberrations in eccrine porocarcinomas and poromas"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3982-9038","authenticated-orcid":false,"given":"Maya","family":"Puttonen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrikki","family":"Almusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"B\u00f6hling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virve","family":"Koljonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harri","family":"Sihto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"12","key":"3586_CR1","first-page":"1227","volume":"29","author":"MA Gonz\u00e1lez-L\u00f3pez","year":"2003","unstructured":"Gonz\u00e1lez-L\u00f3pez MA, V\u00e1zquez-L\u00f3pez F, Soler T, G\u00f3mez-Di\u00e9z S, Garcia YH, Manj\u00f3n JA, et al. Metastatic eccrine porocarcinoma: a 5.6-year follow-up study of a patient treated with a combined therapeutic protocol. Dermatol Surg. 2003;29(12):1227\u201332.","journal-title":"Dermatol Surg."},{"issue":"1","key":"3586_CR2","first-page":"adv00363","volume":"101","author":"AS Merilainen","year":"2021","unstructured":"Merilainen AS, Pukkala E, Bohling T, Koljonen V. Malignant eccrine porocarcinoma in Finland during 2007 to 2017. Acta Derm Venereol. 2021;101(1):adv00363.","journal-title":"Acta Derm Venereol."},{"issue":"16","key":"3586_CR3","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.3390\/diagnostics13162689","volume":"13","author":"E Kyrmanidou","year":"2023","unstructured":"Kyrmanidou E, Fotiadou C, Kemanetzi C, Trakatelli MG, Trigoni A, Patsatsi A, et al. Eccrine poroma: pathogenesis, new diagnostic tools and association with porocarcinoma-a review. Diagnostics (Basel). 2023;13(16):2689.","journal-title":"Diagnostics (Basel)."},{"issue":"8","key":"3586_CR4","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.3390\/diagnostics13081431","volume":"13","author":"A Tsiogka","year":"2023","unstructured":"Tsiogka A, Koumaki D, Kyriazopoulou M, Liopyris K, Stratigos A, Gregoriou S. Eccrine porocarcinoma: a review of the literature. Diagnostics (Basel). 2023;13(8):1431.","journal-title":"Diagnostics (Basel)."},{"key":"3586_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.amsu.2017.06.027","volume":"20","author":"AM Salih","year":"2017","unstructured":"Salih AM, Kakamad FH, Baba HO, Salih RQ, Hawbash MR, Mohammed SH, et al. Porocarcinoma; presentation and management, a meta-analysis of 453 cases. Ann Med Surg (Lond). 2017;20:74\u20139.","journal-title":"Ann Med Surg (Lond)"},{"issue":"5","key":"3586_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1365-2133.2011.10486.x","volume":"165","author":"E Belin","year":"2011","unstructured":"Belin E, Ezzedine K, Stanislas S, Lalanne N, Beylot-Barry M, Taieb A, et al. Factors in the surgical management of primary eccrine porocarcinoma: prognostic histological factors can guide the surgical procedure. Br J Dermatol. 2011;165(5):985\u20139.","journal-title":"Br J Dermatol"},{"issue":"10","key":"3586_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/DSS.0000000000001566","volume":"44","author":"A Nazemi","year":"2018","unstructured":"Nazemi A, Higgins S, Swift R, In G, Miller K, Wysong A. Eccrine porocarcinoma: new insights and a systematic review of the literature. Dermatol Surg. 2018;44(10):1247\u201361.","journal-title":"Dermatol Surg"},{"issue":"6","key":"3586_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/j.1529-8019.2008.00243.x","volume":"21","author":"CW Brown Jr","year":"2008","unstructured":"Brown CW Jr, Dy LC. Eccrine porocarcinoma. Dermatol Ther. 2008;21(6):433\u20138.","journal-title":"Dermatol Ther"},{"issue":"6","key":"3586_CR9","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/00000478-200106000-00002","volume":"25","author":"A Robson","year":"2001","unstructured":"Robson A, Greene J, Ansari N, Kim B, Seed PT, McKee PH, et al. Eccrine porocarcinoma (malignant eccrine poroma): a clinicopathologic study of 69 cases. Am J Surg Pathol. 2001;25(6):710\u201320.","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"3586_CR10","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/ced\/llad122","volume":"48","author":"J Joshy","year":"2023","unstructured":"Joshy J, van Bodegraven B, Mistry K, Craig P, Rajan N, Vernon S, et al. Epidemiology of porocarcinoma in England 2013\u20132018: a population-based registry study. Clin Exp Dermatol. 2023;48(7):770\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"3586_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/DSS.0000000000003652","volume":"49","author":"SD Ragi","year":"2023","unstructured":"Ragi SD, Moseley I, Ouellette S, Rao B. Epidemiology and Survival of eccrine porocarcinoma by sex in the United States: a surveillance, epidemiology, and end results database analysis. Dermatol Surg. 2023;49(1):97\u20139.","journal-title":"Dermatol Surg"},{"issue":"21","key":"3586_CR12","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.3390\/cancers14215232","volume":"14","author":"K Miyamoto","year":"2022","unstructured":"Miyamoto K, Yanagi T, Maeda T, Ujiie H. Diagnosis and management of porocarcinoma. Cancers (Basel). 2022;14(21):5232.","journal-title":"Cancers (Basel)."},{"key":"3586_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.humpath.2015.12.015","volume":"51","author":"PW Harms","year":"2016","unstructured":"Harms PW, Hovelson DH, Cani AK, Omata K, Haller MJ, Wang ML, et al. Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations. Hum Pathol. 2016;51:25\u201331.","journal-title":"Hum Pathol"},{"issue":"3","key":"3586_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.pathol.2017.10.011","volume":"50","author":"M Bosic","year":"2018","unstructured":"Bosic M, Kirchner M, Brasanac D, Leichsenring J, Lier A, Volckmar AL, et al. Targeted molecular profiling reveals genetic heterogeneity of poromas and porocarcinomas. Pathology. 2018;50(3):327\u201332.","journal-title":"Pathology"},{"issue":"9","key":"3586_CR15","doi-asserted-by":"publisher","first-page":"3827","DOI":"10.1172\/JCI126185","volume":"129","author":"S Sekine","year":"2019","unstructured":"Sekine S, Kiyono T, Ryo E, Ogawa R, Wakai S, Ichikawa H, et al. Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma. J Clin Invest. 2019;129(9):3827\u201332.","journal-title":"J Clin Invest"},{"issue":"6","key":"3586_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/1346-8138.14889","volume":"46","author":"S Cavalieri","year":"2019","unstructured":"Cavalieri S, Busico A, Capone I, Conca E, Dallera E, Quattrone P, et al. Identification of potentially druggable molecular alterations in skin adnexal malignancies. J Dermatol. 2019;46(6):507\u201314.","journal-title":"J Dermatol"},{"key":"3586_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00347-z","author":"E Denisova","year":"2021","unstructured":"Denisova E, Westphal D, Surowy HM, Meier F, Hutter B, Reifenberger J, et al. Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies. Cancer Gene Ther. 2021. https:\/\/doi.org\/10.1038\/s41417-021-00347-z.","journal-title":"Cancer Gene Ther."},{"key":"3586_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20604","author":"D Westphal","year":"2021","unstructured":"Westphal D, Garzarolli M, Sergon M, Horak P, Hutter B, Becker JC, et al. High tumour mutational burden and EGFR\/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma. Br J Dermatol. 2021. https:\/\/doi.org\/10.1111\/bjd.20604.","journal-title":"Br J Dermatol."},{"issue":"6","key":"3586_CR19","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/humu.22552","volume":"35","author":"B Leroy","year":"2014","unstructured":"Leroy B, Anderson M, Soussi T. TP53 mutations in human cancer: database reassessment and prospects for the next decade. Hum Mutat. 2014;35(6):672\u201388.","journal-title":"Hum Mutat"},{"issue":"5","key":"3586_CR20","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.cmet.2013.06.019","volume":"18","author":"CR Berkers","year":"2013","unstructured":"Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH. Metabolic regulation by p53 family members. Cell Metab. 2013;18(5):617\u201333.","journal-title":"Cell Metab"},{"issue":"1","key":"3586_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41698-018-0050-5","volume":"2","author":"ML Thibodeau","year":"2018","unstructured":"Thibodeau ML, Bonakdar M, Zhao E, Mungall KL, Reisle C, Zhang W, et al. Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma. NPJ Precis Oncol. 2018;2(1):8.","journal-title":"NPJ Precis Oncol"},{"issue":"7","key":"3586_CR22","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/modpathol.2011.48","volume":"24","author":"D Dias-Santagata","year":"2011","unstructured":"Dias-Santagata D, Lam Q, Bergethon K, Baker GM, Iafrate AJ, Rakheja D, et al. A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas. Mod Pathol. 2011;24(7):974\u201382.","journal-title":"Mod Pathol"},{"issue":"10","key":"3586_CR23","doi-asserted-by":"publisher","first-page":"e47290","DOI":"10.1371\/journal.pone.0047290","volume":"7","author":"LP Le","year":"2012","unstructured":"Le LP, Dias-Santagata D, Pawlak AC, Cosper AK, Nguyen AT, Selim MA, et al. Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses. PLoS ONE. 2012;7(10):e47290.","journal-title":"PLoS ONE"},{"issue":"2","key":"3586_CR24","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462\u201377.","journal-title":"Cell"},{"issue":"8","key":"3586_CR25","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/modpathol.3800438","volume":"18","author":"R Bhargava","year":"2005","unstructured":"Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005;18(8):1027\u201333.","journal-title":"Mod Pathol"},{"issue":"1","key":"3586_CR26","first-page":"48","volume":"2","author":"G Bethune","year":"2010","unstructured":"Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. J Thorac Dis. 2010;2(1):48\u201351.","journal-title":"J Thorac Dis"},{"issue":"8","key":"3586_CR27","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/modpathol.3800137","volume":"17","author":"A Ooi","year":"2004","unstructured":"Ooi A, Takehana T, Li X, Suzuki S, Kunitomo K, Iino H, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol. 2004;17(8):895\u2013904.","journal-title":"Mod Pathol"},{"key":"3586_CR28","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell. 2015;161(7):1681\u201396.","DOI":"10.1016\/j.cell.2015.05.044"},{"issue":"43","key":"3586_CR29","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1038\/onc.2010.314","volume":"29","author":"KB Monahan","year":"2010","unstructured":"Monahan KB, Rozenberg GI, Krishnamurthy J, Johnson SM, Liu W, Bradford MK, et al. Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene. 2010;29(43):5809\u201317.","journal-title":"Oncogene"},{"issue":"5","key":"3586_CR30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1474-9726.2008.00422.x","volume":"7","author":"S Haferkamp","year":"2008","unstructured":"Haferkamp S, Becker TM, Scurr LL, Kefford RF, Rizos H. p16INK4a-induced senescence is disabled by melanoma-associated mutations. Aging Cell. 2008;7(5):733\u201345.","journal-title":"Aging Cell"},{"key":"3586_CR31","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/366704a0","volume":"366","author":"GJH Manuel Serrano","year":"1993","unstructured":"Manuel Serrano GJH, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D\/CDK4. Nature. 1993;366:704\u20137.","journal-title":"Nature."},{"key":"3586_CR32","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","volume":"88","author":"M Serrano","year":"1997","unstructured":"Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 1997;88:593\u2013602.","journal-title":"Cell."},{"issue":"17","key":"3586_CR33","doi-asserted-by":"publisher","first-page":"5001","DOI":"10.1093\/emboj\/17.17.5001","volume":"17","author":"FJ Stott","year":"1998","unstructured":"Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S, et al. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 1998;17(17):5001\u201314.","journal-title":"EMBO J"},{"issue":"9","key":"3586_CR34","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41416-024-02852-y","volume":"131","author":"D Prasad","year":"2024","unstructured":"Prasad D, Baldelli E, Blais EM, Davis J, El Gazzah E, Mueller C, et al. Functional activation of the AKT-mTOR signalling axis in a real-world metastatic breast cancer cohort. Br J Cancer. 2024;131(9):1543\u201354.","journal-title":"Br J Cancer"},{"issue":"8","key":"3586_CR35","doi-asserted-by":"publisher","first-page":"772","DOI":"10.4161\/cbt.3.8.994","volume":"3","author":"KE Bachman","year":"2004","unstructured":"Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004;3(8):772\u20135.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"3586_CR36","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s43018-021-00184-x","volume":"2","author":"S Mukhopadhyay","year":"2021","unstructured":"Mukhopadhyay S, Vander Heiden MG, McCormick F. The metabolic landscape of RAS-driven cancers from biology to therapy. Nat Cancer. 2021;2(3):271\u201383.","journal-title":"Nat Cancer"},{"key":"3586_CR37","doi-asserted-by":"publisher","DOI":"10.1111\/his.15023","author":"T Kervarrec","year":"2023","unstructured":"Kervarrec T, Pissaloux D, Tirode F, de la Fouchardiere A, Sohier P, Frouin E, et al. Gene fusions in poroma, porocarcinoma and related adnexal skin tumours: an update. Histopathology. 2023. https:\/\/doi.org\/10.1111\/his.15023.","journal-title":"Histopathology."},{"key":"3586_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02382-1","author":"S Behera","year":"2024","unstructured":"Behera S, Catreux S, Rossi M, Truong S, Huang Z, Ruehle M, et al. Comprehensive genome analysis and variant detection at scale using DRAGEN. Nat Biotechnol. 2024. https:\/\/doi.org\/10.1038\/s41587-024-02382-1.","journal-title":"Nat Biotechnol."},{"issue":"16","key":"3586_CR39","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164.","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"3586_CR40","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.ajhg.2016.08.016","volume":"99","author":"NM Ioannidis","year":"2016","unstructured":"Ioannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: an ensemble method for predicting the pathogenicity of rare missense variants. Am J Hum Genet. 2016;99(4):877\u201385.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"3586_CR41","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/bioinformatics\/btw572","volume":"33","author":"RA Rosales","year":"2017","unstructured":"Rosales RA, Drummond RD, Valieris R, Dias-Neto E, da Silva IT. signeR: an empirical Bayesian approach to mutational signature discovery. Bioinformatics. 2017;33(1):8\u201316.","journal-title":"Bioinformatics"},{"issue":"1","key":"3586_CR42","doi-asserted-by":"publisher","first-page":"18217","DOI":"10.1038\/s41598-020-75062-0","volume":"10","author":"D Fantini","year":"2020","unstructured":"Fantini D, Vidimar V, Yu Y, Condello S, Meeks JJ. MutSignatures: an R package for extraction and analysis of cancer mutational signatures. Sci Rep. 2020;10(1):18217.","journal-title":"Sci Rep"},{"issue":"7793","key":"3586_CR43","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","volume":"578","author":"LB Alexandrov","year":"2020","unstructured":"Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578(7793):94\u2013101.","journal-title":"Nature"},{"issue":"W1","key":"3586_CR44","doi-asserted-by":"publisher","first-page":"W566","DOI":"10.1093\/nar\/gkv468","volume":"43","author":"T Metsalu","year":"2015","unstructured":"Metsalu T, Vilo J. ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap. Nucleic Acids Res. 2015;43(W1):W566\u201370.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"3586_CR45","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/humu.24309","volume":"43","author":"S Gudmundsson","year":"2022","unstructured":"Gudmundsson S, Singer-Berk M, Watts NA, Phu W, Goodrich JK, Solomonson M, et al. Variant interpretation using population databases: lessons from gnomAD. Hum Mutat. 2022;43(8):1012\u201330.","journal-title":"Hum Mutat"},{"key":"3586_CR46","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"E Chen","year":"2013","unstructured":"Chen E, Tan C, Kou Y, Duan Q, Wang Z, Meirelles G, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013;14:128.","journal-title":"BMC Bioinform."},{"issue":"W1","key":"3586_CR47","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"3586_CR48","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/cpz1.90","volume":"1","author":"Z Xie","year":"2021","unstructured":"Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene set knowledge discovery with enrichr. Curr Protoc. 2021;1(3):e90.","journal-title":"Curr Protoc"},{"issue":"6360","key":"3586_CR49","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1126\/science.aao3130","volume":"358","author":"J Drost","year":"2017","unstructured":"Drost J, van Boxtel R, Blokzijl F, Mizutani T, Sasaki N, Sasselli V, et al. Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer. Science. 2017;358(6360):234\u20138.","journal-title":"Science"},{"key":"3586_CR50","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.isci.2019.08.024","volume":"19","author":"A Ahad","year":"2019","unstructured":"Ahad A, Stevanin M, Smita S, Mishra GP, Gupta D, Waszak S, et al. NCoR1: putting the brakes on the dendritic cell immune tolerance. iScience. 2019;19:996\u20131011.","journal-title":"iScience."},{"key":"3586_CR51","doi-asserted-by":"publisher","first-page":"630773","DOI":"10.3389\/fimmu.2021.630773","volume":"12","author":"A Lin","year":"2021","unstructured":"Lin A, Qiu Z, Zhang J, Luo P. Effect of NCOR1 mutations on immune microenvironment and efficacy of immune checkpoint inhibitors in patient with bladder cancer. Front Immunol. 2021;12:630773.","journal-title":"Front Immunol"},{"issue":"11","key":"3586_CR52","first-page":"e20004","volume":"13","author":"A Singh","year":"2021","unstructured":"Singh A, Nguyen L, Everest S, Vinogradov M. Metastatic porocarcinoma effectively managed by pembrolizumab. Cureus. 2021;13(11):e20004.","journal-title":"Cureus"},{"issue":"2","key":"3586_CR53","doi-asserted-by":"publisher","first-page":"e12830","DOI":"10.1111\/dth.12830","volume":"32","author":"T Nagasawa","year":"2019","unstructured":"Nagasawa T, Hirata A, Niiyama S, Enomoto Y, Fukuda H. Successful treatment of porocarcinoma with maxacalcitol and imiquimod. Dermatol Ther. 2019;32(2):e12830.","journal-title":"Dermatol Ther"},{"key":"3586_CR54","doi-asserted-by":"publisher","first-page":"864302","DOI":"10.3389\/fmolb.2022.864302","volume":"9","author":"JE Fromme","year":"2022","unstructured":"Fromme JE, Zigrino P. The role of extracellular matrix remodeling in skin tumor progression and therapeutic resistance. Front Mol Biosci. 2022;9:864302.","journal-title":"Front Mol Biosci"},{"key":"3586_CR55","doi-asserted-by":"publisher","first-page":"924553","DOI":"10.3389\/fonc.2022.924553","volume":"12","author":"A Popovic","year":"2022","unstructured":"Popovic A, Tartare-Deckert S. Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance. Front Oncol. 2022;12:924553.","journal-title":"Front Oncol"},{"issue":"728","key":"3586_CR56","doi-asserted-by":"publisher","first-page":"eadj3840","DOI":"10.1126\/scitranslmed.adg3840","volume":"16","author":"JJF Sleeboom","year":"2024","unstructured":"Sleeboom JJF, van Tienderen GS, Schenke-Layland K, van der Laan LJW, Khalil AA, Verstegen MMA. The extracellular matrix as hallmark of cancer and metastasis: from biomechanics to therapeutic targets. Sci Transl Med. 2024;16(728):eadj3840.","journal-title":"Sci Transl Med."},{"issue":"3","key":"3586_CR57","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.21873\/invivo.12385","volume":"35","author":"J Pogorzelska-Dyrbus","year":"2021","unstructured":"Pogorzelska-Dyrbus J, Szepietowski JC. Adhesion molecules in non-melanoma skin cancers: a comprehensive review. In Vivo. 2021;35(3):1327\u201336.","journal-title":"In Vivo"},{"issue":"8","key":"3586_CR58","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.3390\/biom11081213","volume":"11","author":"C D\u2019Arcy","year":"2021","unstructured":"D\u2019Arcy C, Kiel C. Cell adhesion molecules in normal skin and melanoma. Biomolecules. 2021;11(8):1213.","journal-title":"Biomolecules."},{"issue":"1","key":"3586_CR59","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41392-021-00544-0","volume":"6","author":"J Huang","year":"2021","unstructured":"Huang J, Zhang L, Wan D, Zhou L, Zheng S, Lin S, et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct Target Ther. 2021;6(1):153.","journal-title":"Signal Transduct Target Ther"},{"issue":"23","key":"3586_CR60","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357\u201364.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3586_CR61","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1365-2559.2012.04203.x","volume":"61","author":"S Huss","year":"2012","unstructured":"Huss S, Wardelmann E, Goltz D, Binot E, Hartmann W, Merkelbach-Bruse S, et al. Activating PDGFRA mutations in inflammatory fibroid polyps occur in exons 12, 14 and 18 and are associated with tumour localization. Histopathology. 2012;61(1):59\u201368.","journal-title":"Histopathology"},{"issue":"3","key":"3586_CR62","doi-asserted-by":"publisher","first-page":"100070","DOI":"10.1016\/j.modpat.2022.100070","volume":"36","author":"R Iwamura","year":"2023","unstructured":"Iwamura R, Komatsu K, Kusano M, Kubo C, Inaba Y, Shiba E, et al. PDGFRB and NOTCH3 mutations are detectable in a wider range of pericytic tumors, including myopericytomas, angioleiomyomas, glomus tumors, and their combined tumors. Mod Pathol. 2023;36(3):100070.","journal-title":"Mod Pathol"},{"issue":"6","key":"3586_CR63","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ajhg.2013.04.026","volume":"92","author":"YH Cheung","year":"2013","unstructured":"Cheung YH, Gayden T, Campeau PM, LeDuc CA, Russo D, Nguyen VH, et al. A recurrent PDGFRB mutation causes familial infantile myofibromatosis. Am J Hum Genet. 2013;92(6):996\u20131000.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"3586_CR64","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1159\/000518442","volume":"13","author":"AJ Jabbour","year":"2021","unstructured":"Jabbour AJ, Tangoren IA, Kanik AB. Digital papillary adenocarcinoma: case of a rare malignant cutaneous tumor of the eccrine sweat gland. Case Rep Dermatol. 2021;13(2):422\u20137.","journal-title":"Case Rep Dermatol"},{"issue":"1","key":"3586_CR65","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/2159-8290.CD-22-0489","volume":"13","author":"L Leiendecker","year":"2023","unstructured":"Leiendecker L, Neumann T, Jung PS, Cronin SM, Steinacker TL, Schleiffer A, et al. Human papillomavirus 42 drives digital papillary adenocarcinoma and elicits a germ cell-like program conserved in HPV-positive cancers. Cancer Discov. 2023;13(1):70\u201384.","journal-title":"Cancer Discov"},{"issue":"7484","key":"3586_CR66","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505(7484):495\u2013501.","journal-title":"Nature"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03586-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03586-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T09:08:34Z","timestamp":1739437714000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03586-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3586"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03586-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional ethics committee of Helsinki University Central Hospital [HUS\/358\/2018].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}